These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

182 related articles for article (PubMed ID: 28207808)

  • 1. Autologous hematopoietic stem cell transplantation in lymphoma patients is associated with a decrease in the double strand break repair capacity of peripheral blood lymphocytes.
    Lacoste S; Bhatia S; Chen Y; Bhatia R; O'Connor TR
    PLoS One; 2017; 12(2):e0171473. PubMed ID: 28207808
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Accelerated telomere shortening precedes development of therapy-related myelodysplasia or acute myelogenous leukemia after autologous transplantation for lymphoma.
    Chakraborty S; Sun CL; Francisco L; Sabado M; Li L; Chang KL; Forman S; Bhatia S; Bhatia R
    J Clin Oncol; 2009 Feb; 27(5):791-8. PubMed ID: 19124806
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Longitudinal assessment of hematopoietic abnormalities after autologous hematopoietic cell transplantation for lymphoma.
    Bhatia R; Van Heijzen K; Palmer A; Komiya A; Slovak ML; Chang KL; Fung H; Krishnan A; Molina A; Nademanee A; O'Donnell M; Popplewell L; Rodriguez R; Forman SJ; Bhatia S
    J Clin Oncol; 2005 Sep; 23(27):6699-711. PubMed ID: 16170178
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Granulocytes affect double-strand break repair assays in primary human lymphocytes.
    Lacoste S; Bhatia R; Bhatia S; O'Connor TR
    PLoS One; 2014; 9(3):e93185. PubMed ID: 24667872
    [TBL] [Abstract][Full Text] [Related]  

  • 5. DNA Repair Capacity for Personalizing Risk and Treatment Response - Assay Development and Optimization in Human Peripheral Blood Mononuclear Cells (PBMCs).
    Nasrallah NA; Zhou H; Smith PA; Sears CR
    DNA Repair (Amst); 2022 Mar; 111():103274. PubMed ID: 35085879
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Incidence of post transplant myelodysplasia/acute leukemia in non-Hodgkin's lymphoma patients compared with Hodgkin's disease patients undergoing autologous transplantation following cyclophosphamide, carmustine, and etoposide (CBV).
    Wheeler C; Khurshid A; Ibrahim J; Elias A; Mauch P; Ault K; Antin J
    Leuk Lymphoma; 2001 Feb; 40(5-6):499-509. PubMed ID: 11426523
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Results of a Multicenter Phase II Trial of Brentuximab Vedotin as Second-Line Therapy before Autologous Transplantation in Relapsed/Refractory Hodgkin Lymphoma.
    Chen R; Palmer JM; Martin P; Tsai N; Kim Y; Chen BT; Popplewell L; Siddiqi T; Thomas SH; Mott M; Sahebi F; Armenian S; Leonard J; Nademanee A; Forman SJ
    Biol Blood Marrow Transplant; 2015 Dec; 21(12):2136-2140. PubMed ID: 26211987
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Periodic morphologic, cytogenetic and clonality evaluation after autologous peripheral blood progenitor cell transplantation in patients with lymphoproliferative malignancies.
    Laurenti L; Chiusolo P; Garzia MG; Zini G; Sorà F; Piccirillo N; Piccioni P; Zollino M; Leone G; Sica S
    Haematologica; 2002 Jan; 87(1):59-66. PubMed ID: 11801466
    [TBL] [Abstract][Full Text] [Related]  

  • 9. High risk of therapy-related leukemia after BEAM chemotherapy and autologous stem cell transplantation for previously treated lymphomas is mainly related to primary chemotherapy and not to the BEAM-transplantation procedure.
    Pedersen-Bjergaard J; Pedersen M; Myhre J; Geisler C
    Leukemia; 1997 Oct; 11(10):1654-60. PubMed ID: 9324285
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Therapy-related myelodysplasia and acute myeloid leukemia.
    Bhatia S
    Semin Oncol; 2013 Dec; 40(6):666-75. PubMed ID: 24331189
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Simplified validated prognostic model for progression-free survival after autologous transplantation for hodgkin lymphoma.
    Hahn T; McCarthy PL; Carreras J; Zhang MJ; Lazarus HM; Laport GG; Montoto S; Hari PN
    Biol Blood Marrow Transplant; 2013 Dec; 19(12):1740-4. PubMed ID: 24096096
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Impact of conditioning regimen on outcomes for patients with lymphoma undergoing high-dose therapy with autologous hematopoietic cell transplantation.
    Chen YB; Lane AA; Logan B; Zhu X; Akpek G; Aljurf M; Artz A; Bredeson CN; Cooke KR; Ho VT; Lazarus HM; Olsson R; Saber W; McCarthy P; Pasquini MC
    Biol Blood Marrow Transplant; 2015 Jun; 21(6):1046-1053. PubMed ID: 25687795
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Autologous stem-cell transplantation after second-line brentuximab vedotin in relapsed or refractory Hodgkin lymphoma.
    Herrera AF; Palmer J; Martin P; Armenian S; Tsai NC; Kennedy N; Sahebi F; Cao T; Budde LE; Mei M; Siddiqi T; Popplewell L; Rosen ST; Kwak LW; Nademanee A; Forman SJ; Chen R
    Ann Oncol; 2018 Mar; 29(3):724-730. PubMed ID: 29272364
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Positron Emission Tomography-Based Assessment of Metabolic Tumor Volume Predicts Survival after Autologous Hematopoietic Cell Transplantation for Hodgkin Lymphoma.
    Procházka V; Gawande RS; Cayci Z; Froelich JW; Cao Q; Wilke C; Dusenbery K; Weisdorf DJ; Bachanova V
    Biol Blood Marrow Transplant; 2018 Jan; 24(1):64-70. PubMed ID: 28942016
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Autologous haematopoietic cell transplantation for non-Hodgkin lymphoma with secondary CNS involvement.
    Maziarz RT; Wang Z; Zhang MJ; Bolwell BJ; Chen AI; Fenske TS; Freytes CO; Gale RP; Gibson J; Hayes-Lattin BM; Holmberg L; Inwards DJ; Isola LM; Khoury HJ; Lewis VA; Maharaj D; Munker R; Phillips GL; Rizzieri DA; Rowlings PA; Saber W; Satwani P; Waller EK; Maloney DG; Montoto S; Laport GG; Vose JM; Lazarus HM; Hari PN
    Br J Haematol; 2013 Sep; 162(5):648-56. PubMed ID: 23829536
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Is Cytomegalovirus Surveillance Necessary for Patients With Low Reactivation Risk in an Autologous Hematopoietic Cell Transplantation Setting?
    Kaya AH; Tekgunduz E; Akpinar S; Batgi H; Bekdemir F; Kayikci O; Namdaroglu S; Ulu BU; Dal MS; Cakar MK; Korkmaz S; Altuntas F
    Transplant Proc; 2017 Oct; 49(8):1911-1915. PubMed ID: 28923647
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Finding the Optimal Conditioning Regimen for Relapsed/Refractory Lymphoma Patients Undergoing Autologous Hematopoietic Cell Transplantation: A Retrospective Comparison of BEAM and High-Dose ICE.
    Esbah O; Tekgündüz E; Şirinoğlu Demiriz I; Civriz Bozdağ S; Kaya A; Tetik A; Kayıkçı Ö; Durgun G; Kocubaba Ş; Altuntaş F
    Turk J Haematol; 2016 Sep; 33(3):209-15. PubMed ID: 26377357
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Secondary acute myeloid leukemia and myelodysplasia after autologous peripheral blood progenitor cell transplantation.
    Sevilla J; Rodríguez A; Hernández-Maraver D; de Bustos G; Aguado J; Ojeda E; Arrieta R; Hernández-Navarro F
    Ann Hematol; 2002 Jan; 81(1):11-5. PubMed ID: 11807629
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Functional DNA repair system analysis in haematopoietic progenitor cells using host cell reactivation.
    Thoms KM; Baesecke J; Emmert B; Hermann J; Roedling T; Laspe P; Leibeling D; Truemper L; Emmert S
    Scand J Clin Lab Invest; 2007; 67(6):580-8. PubMed ID: 17852814
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Lomustine, cytarabine, cyclophosphamide, etoposide - An effective conditioning regimen in autologous hematopoietic stem cell transplant for primary refractory or relapsed lymphoma: Analysis of toxicity, long-term outcome, and prognostic factors.
    Gupta A; Gokarn A; Rajamanickam D; Punatar S; Thippeswamy R; Mathew L; Bagal B; Kannan S; Khattry N
    J Cancer Res Ther; 2018; 14(5):926-933. PubMed ID: 30197327
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 10.